Haoduo Zhao

Dr. Haoduo Zhao

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
JFJiahao Feng
Jiahao Feng
JPJingya Peng
Jingya Peng
YHYun-Chung Hsiao
Yun-Chung Hsiao
CLChih-Wei Liu
Chih-Wei Liu
YYYifei Yang
Yifei Yang
KLKun Lu
Kun Lu
Background: Non/low-caloric artificial sweeteners (NAS) are recognized as chemical additives substituting sugars to avoid caloric intake and subsequent sugar-derived diseases such as diabetes and hyperglycemia. Six NAS have been claimed safe and are authorized by the US Food and Drug Administration (FDA) for public use, with acceptable daily intake information available: aspartame, acesulfame-K, saccharin, sucralose, neotame, and advantame. However, the impacts of NAS on the gut microbiome have raised potential concerns, since sporadic research revealed NAS-induced microbial changes in the gastrointestinal tracts and alterations in the microbiome–host interactive metabolism. Methods: Given the fact that the gut microbiome influences kaleidoscopic physiological functions in host health, this review aimed to decipher the impacts of NAS on the gut microbiome by implementing a comprehensive two-stage literature analysis based on each NAS. Results: This review documented disturbed microbiomes due to NAS exposure to a maximal resolution of species level using taxonomic clustering analysis, and recorded metabolism alterations involved in gut microbiome–host interactions. Conclusions: The results elucidated that specific NAS exhibited discrepant impacts on the gut microbiome, even though overlapping on the genera and species were identified. Some NAS caused glucose tolerance impairment in the host, but the key metabolites and their underlying mechanisms were different. Furthermore, this review embodied the challenges and future directions of current NAS–gut microbiome research to inspire advanced examination of the NAS exposure–gut microbiome–host metabolism axis.

1 February 2023 in DNA
Verified
Journal Article
Open access
PDF file
YHYun-Chung Hsiao
Yun-Chung Hsiao
CLChih-Wei Liu
Chih-Wei Liu
YYYifei Yang
Yifei Yang
JFJiahao Feng
Jiahao Feng
HZHaoduo Zhao
Haoduo Zhao
KLKun Lu
Kun Lu
Both the number of cells and the collective genome of the gut microbiota outnumber their mammalian hosts, and the metabolic and physiological interactions of the gut microbiota with the host have not yet been fully characterized. Cancer remains one of the leading causes of death, and more research into the critical events that can lead to cancer and the importance of the gut microbiota remains to be determined. The gut microbiota can release microbial molecules that simulate host endogenous processes, such as inflammatory responses, or can alter host metabolism of ingested substances. Both of these reactions can be beneficial or deleterious to the host, and some can be genotoxic, thus contributing to cancer progression. This review focused on the molecular evidence currently available on the mechanistic understanding of how the gut microbiota are involved in human carcinogenesis. We first reviewed the key events of carcinogenesis, especially how DNA damage proceeds to tumor formulation. Then, the current knowledge on host DNA damage attributed to the gut microbiota was summarized, followed by the genotoxic endogenous processes the gut microbiota can induce. Finally, we touched base on the association between specific gut microbiota dysbiosis and different types of cancer and concluded with the up-to-date knowledge as well as future research direction for advancing our understanding of the relationship between the gut microbiota and cancer development.

22 October 2025 in Environmental Science & Technology
Verified
Journal Article
Closed access
HZHaoduo Zhao
Haoduo Zhao
YHYun-Chung Hsiao
Yun-Chung Hsiao
CLChih-Wei Liu
Chih-Wei Liu
JFJiahao Feng
Jiahao Feng
XWXueying Wang
Xueying Wang
KLKun Lu
Kun Lu

26 May 2026 in Nature Communications
Verified
Journal Article
Open access
HZHaoduo Zhao
Haoduo Zhao
LCLiang Chi
Liang Chi
ZZZhenfa Zhang
Zhenfa Zhang
YHYun-Chung Hsiao
Yun-Chung Hsiao
CLChih-Wei Liu
Chih-Wei Liu
KLKun Lu
Kun Lu
Gut microbiota exert significant influences on host physiology through bioactive molecules such as indole derivatives. The characteristic aromatic heterocycle substructure shared among various indole derivatives is intrinsically associated with the activation of aryl hydrocarbon receptor (AhR), suggesting a potential structure-activity relationship (SAR). Here, we develop a substructure-activity relationship mass spectrometry pipeline aiming at elucidating SAR information encompassed within mass spectrometry data, further applying it to identify the unknown gut microbiome-derived, indole-like derivatives with AhR agonistic potential. A total of 22 metabolites exhibiting activity-related substructures are identified, four of which were previously uncharacterized. Notably, the discovered sulfonated and methylthiolated compounds represent two previously underexplored microbiome-mediated reactions. Subsequent assays validate their AhR agonistic activities and downstream immune regulatory effects in male mice. Overall, this study presents an exploratory framework for MS data mining focusing on activity-guided substructure prioritization, enabling the discovery of bioactive microbiota-derived molecules and distinct microbiome-mediated reactions.

30 September 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
Taylor TeitelbaumTaylor Teitelbaum
Taylor Teitelbaum
HZHaoduo Zhao
Haoduo Zhao
LKLauren Koval
Lauren Koval
YHYun-Chung Hsiao
Yun-Chung Hsiao
CLChih-Wei Liu
Chih-Wei Liu
KLKun Lu
Kun Lu
Background: Environmental chemicals are hypothesized to contribute to the development of neurodevelopmental disorders; however, only a fraction of the thousands of chemicals in common commercial use have validated assays. We recently developed the Environmental NeuRoactIve Chemicals (ENRICH) list of 250 chemicals prioritized for further testing due to their high likelihood of neuroactivity and human exposure, as derived through analysis across eight neuroactivity, exposure, and detection databases. Measuring some of these compounds in human biological media remains challenging due to the lack of information regarding their metabolites and detection frequencies. Methods: We created an LC-MS/MS database based on the targets in the ENRICH list using S9 human liver fractions to metabolize compounds individually and in groups into newly and previously discovered phase I metabolites. Results: The final database consisted of 274 compounds with 94 parent compounds and 182 metabolites being featured. A total of 55 novel metabolites were discovered. The confidence of the compounds, which were annotated correctly within the database, was high, increasing the odds of positive identifications within future exposomic work. The confidence of the annotations fell between the levels 1–3, with levels one and two consisting of 87% of the database. Conclusions: The creation of this database creates the opportunity for future biological studies centered around the impact these compounds and their metabolites have on the brain and for a better understanding of neurodevelopmental disorders and their origins.

12 June 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
HZHaoduo Zhao
Haoduo Zhao
YHYun-Chung Hsiao
Yun-Chung Hsiao
CLChih-Wei Liu
Chih-Wei Liu
JFJiahao Feng
Jiahao Feng
XWXueying Wang
Xueying Wang
KLKun Lu
Kun Lu
Human exposome features a highly expansive chemical space and substantial individual variability. Although screenings of xenobiotic compounds have revealed exposure landscapes of specific compounds, significant bottlenecks remain in profiling their biotransformed products for comprehensive exposome-wide analysis, including limitations to known metabolites, challenges in new metabolite annotation and low throughput. In this study, we develop an untargeted metabolomics-based compound metabolite discovery network (CMDN) to facilitate high-throughput annotation of xenobiotic metabolites. CMDN integrates a triple-layered architecture comprising a differential expression metabolic space, a rule-based pseudo-MS1 candidature space and an MS2 spectrum similarity network. The utilities and advantages are demonstrated using pesticides as a representative example, given their widespread human exposure and well-documented toxicity. Coupled with enzymatic biotransformation assays involving 1,021 pesticides, CMDN non-redundantly annotated 2,886 bio-transformed derivatives. Following multi-channel validation including standard verification, retention time prediction, murine studies, and enzymatic kinetics, identified metabolites were screened in a human cohort, revealing a novel, diverse and extensive exposure spectrum. Collectively, this study establishes, for the first time, a scalable workflow for the annotation and screening of previously undercharacterized xenobiotic metabolites with unprecedented throughput, representing a significant advancement towards the characterization, interpretation, and prioritization of the human exposome.